trending Market Intelligence /marketintelligence/en/news-insights/trending/bu5xobeXZBHsbvIdesgnXw2 content esgSubNav
In This List

GE's AI X-ray device approved by US FDA to detect collapsed lungs

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


GE's AI X-ray device approved by US FDA to detect collapsed lungs

General Electric Co. said the U.S. Food and Drug Administration has approved its mobile X-ray device that uses artificial intelligence to speed up the review of collapsed lung cases.

The FDA granted 510(k) clearance to the Critical Care Suite, which was developed by GE Healthcare Inc., the healthcare business of GE, in collaboration with the University of California, South Francisco.

The company's mobile X-ray device uses artificial intelligence algorithms to automatically analyze images and alert a radiologist about a suspected collapsed lung. Known as a pneumothorax, a collapsed lung is when air leaks into the space between the lung and chest wall, causing the organ to collapse.

GE Healthcare said in a Sept. 12 press release that the AI device will cut down the processing time for a radiologist's review that can take up to eight hours in current settings.

The Critical Care Suite was developed using GE Healthcare's Edison platform, which integrates data from multiple sources and applies analytics and artificial intelligence to provide actionable insights.

GE Healthcare provides medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies.